First AD

Second AD

Lack of confidence in biosimilars among health care practitioners

Nocebo/failure to properly educate patients about biosimilars

Differences between biosimilars and originator agents

Lack of clear policy on managing patients with negative outcomes

Reverse switching is a concern for health care centers that are attempting to introduce value-based care. Studies have shown that strong patient and staff education efforts can reduce reverse switching and improve outcomes with biosimilars. In addition, investigators have reported that 

can strongly influence patient willingness to use biosimilars and persist in treatment. It has also been reported that physicians may revert to originators because their health care centers 

 on management of adverse reactions. The 

 has been identified as a major reason for reverse switching. 

Polls

News

Rheumatology

Clinical

Business & Practice

Policy

Oncology

Ophthalmology

Gastroenterology

Dermatology

Reverse switching occurs when patients transitioned to or initiated on a biosimilar are changed to an originator product, often because of a perceived failure in the biosimilar therapy.

Poll: Identify the Main Cause for Reverse Switching